雄激素水平变化对多囊卵巢综合征伴非酒精性脂肪性肝病患者的影响

摘要/Abstract

摘要： 目的雄激素水平变化在多囊卵巢综合征(PCOS)伴非酒精性脂肪性肝病(NAFLD)患者中的影响分析。方法纳入2010年2月至2019年4月期间我院救治的PCOS及PCOS伴NAFLD患者。PCOS诊断符合Rotterdam标准。NAFLD诊断符合非酒精性脂肪性肝病诊疗指南(2010年经中华医学会肝脏病分会修订)。计量资料用(±s)表示, t检验作比较;计数资料以(%)表示, 卡方检验作比较。多因素分析用以探讨各项临床资料对PCOS伴NAFLD患者的影响因素分析。结果研究共纳入符合标准PCOS患者138例(PCOS组), 平均年龄(30.2±2.5)岁;PCOS伴NAFLD患者78例(PCOS伴NAFLD组), 平均年龄(29.5±3.4)岁。两组患者中体质指数、空腹血糖(FPG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、黄体生成素(LH)、卵巢雌激素(FSH)及睾酮均存有显著差异(P<0.05), 而两组患者中谷丙转氨酶、谷草转氨酶、糖化血红蛋白(HbA1c)及雌激素均无明显统计学差异(P>0.05)。将是否存有NAFLD作因变量, 即存有NAFLD赋值为1、无NAFLD赋值为2, 把体质指数、FPG、TC、HDL、LDL、LH、FSH及睾酮纳入二分类logistic回归分析中, 结果提示睾酮是PCOS患者伴发NAFLD的独立危险因素(P<0.05), 而HDL是PCOS患者伴发NAFLD的保护性因素(P<0.05)。结论雄激素水平上升是PCOS伴NAFLD患者的独立危险因素, 针对PCOS伴NAFLD患者的高雄激素的治疗具有重要的临床价值。

关键词: 多囊卵巢综合征, 非酒精性脂肪性肝病, 雄激素, Logistic回归分析

邓永红, 王璟, 王晓莉, 李文霞, 熊万春. 雄激素水平变化对多囊卵巢综合征伴非酒精性脂肪性肝病患者的影响[J]. 肝脏, 2020, 25(6): 622-624.

参考文献 15

[1]	Welt CK, Gudmundsson JA, Arason G. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab, 2006, 91:4842-4848.
[2]	Jin P, Xie Y. Treatment strategies for women with polycystic ovary syndrome. Gynecol Endocrinol, 2018, 34:272-277.
[3]	Bergh CM, Moore M, Gundell C. Evidence-based management of infertility in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs, 2016, 45:111-122.
[4]	Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev, 2017, 49:197-211.
[5]	Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol, 2017, 23:6549-6570.
[6]	Yki-J rvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol, 2014, 2:901-910.
[7]	Tanaka N, Kimura T, Fujimori N, et al. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol, 2019, 25:163-177.
[8]	Mikolasevic I, Orlic L, Franjic N, et al. Transient elastography (FibroScan(?)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. World J Gastroenterol, 2016, 22:7236-7251.
[9]	Neven ACH, Laven J, Teede HJ, et al. A summary on polycystic ovary syndrome: diagnostic criteria, prevalence, clinical manifestations, and management according to the latest international guidelines. Semin Reprod Med, 2018, 36:5-12.
[10]	Rocha ALL, Faria LC, Guimar es TCM, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Invest, 2017, 40:1279-1288.
[11]	Marciniak A, Nawrocka Rutkowska J, et al. Cardiovascular system diseases in patients with polycystic ovary syndrome - the role of inflammation process in this pathology and possibility of early diagnosis and prevention. Ann Agric Environ Med, 2016, 23:537-541.
[12]	Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?. Endocrine, 2016, 51:211-221.
[13]	Kumarendran B, O′Reilly MW, Manolopoulos KN, et al. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. PLoS Med, 2018, 15:e1002542.
[14]	吴佳愉, 范建高. 多囊卵巢综合征与非酒精性脂肪性肝病. 中华糖尿病杂志, 2009, 1:407-409.
[15]	Vassilatou E, Lafoyianni S, Vryonidou A, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod, 2010, 25:212-220.